What Is the Survival Rate of Spleen Cancer?

Survival rates for spleen cancer range from under 20 percent at one year to above 90 percent at five years, depending almost entirely on what type of cancer is involved. The spleen can harbor several very different malignancies, from slow-growing lymphomas with near-normal life expectancy to aggressive angiosarcomas that kill within months. Because “spleen cancer” is not a single disease, any single survival number would be misleading, and the real answer requires looking at each type separately.

Why “Spleen Cancer” Covers Very Different Diseases

Primary cancers that originate in the spleen are rare. Outside of lymphoma involving the spleen, other primary and secondary splenic tumors are infrequently encountered in clinical practice.¹ The two main primary malignancies are lymphoma (which itself comes in multiple subtypes) and angiosarcoma. The spleen can also develop benign growths like hemangiomas and cysts, which are not cancerous and have excellent outcomes. Then there is a third category: cancers from elsewhere in the body that spread to the spleen as metastases. Each of these scenarios carries a fundamentally different prognosis, which is why asking about “spleen cancer survival” without specifying the type is a bit like asking about “lung disease survival” without distinguishing pneumonia from lung cancer.

Among the primary malignancies, splenic marginal zone lymphoma, splenic diffuse large B-cell lymphoma, hairy cell leukemia, and splenic angiosarcoma represent a diagnostically challenging group that can disrupt the spleen’s normal architecture and immune functions.² Because each behaves differently at the cellular level, the survival statistics diverge dramatically.

Splenic Marginal Zone Lymphoma

Splenic marginal zone lymphoma (SMZL) is the most common primary cancer of the spleen, and fortunately it tends to be one of the most survivable. It is a low-grade, slow-growing lymphoma that often follows an indolent course. One single-center study found a 10-year overall survival of about 95 percent, with survival rates essentially overlapping those of the general population.³ That is an extraordinary number for any cancer diagnosis.

However, those results come from a specialized center, and real-world data from broader populations paint a somewhat less rosy picture. A national analysis of SMZL patients treated in the rituximab era reported three-year and five-year overall survival rates of roughly 82 percent and 74 percent, respectively.⁴ The gap between the two studies likely reflects the fact that national databases capture a wider range of patients, including older and sicker individuals who may not make it to a specialized lymphoma center. Patients with few risk factors can reasonably expect outcomes closer to the optimistic end of that range, while those with certain lab abnormalities face worse odds.

A prognostic model developed specifically for SMZL found that outcomes shift considerably depending on three blood markers: hemoglobin level, LDH level, and albumin level. Patients with none of those markers in an unfavorable range had a five-year disease-specific survival of about 88 percent. One unfavorable marker dropped that to roughly 73 percent, and two or three unfavorable markers brought it down to around 50 percent.⁵ So even within a single diagnosis, the survival picture varies depending on how a patient’s body is handling the disease at the time of diagnosis.

Splenic Diffuse Large B-Cell Lymphoma

Diffuse large B-cell lymphoma (DLBCL) of the spleen is a more aggressive cancer than SMZL, but it still responds reasonably well to treatment. A study examining outcomes found a five-year overall survival of about 77 percent and a five-year progression-free survival of roughly 67 percent across all patients.⁶ Those numbers are encouraging for a disease classified as aggressive lymphoma.

What made the data especially interesting was the difference seen when patients had their spleen removed at the time of diagnosis. Patients who underwent splenectomy had a five-year overall survival of about 91 percent, compared with 68 percent for those who did not. For the subgroup with early-stage disease, splenectomy pushed five-year overall survival to 96 percent versus 63 percent without it.⁶ Splenectomy in this setting appears to offer both a diagnostic benefit (confirming the disease) and a therapeutic one (removing the main mass of tumor), especially when the cancer has not yet spread beyond the spleen.

Splenic Angiosarcoma

At the opposite end of the survival spectrum sits primary splenic angiosarcoma, a rare and ferocious cancer that arises from the cells lining blood vessels in the spleen. The outcomes are grim. A retrospective study from China reported a one-year overall survival rate of just 19 percent, with a median survival time of about eight months.⁷ Even with surgery to remove the spleen, angiosarcoma tends to recur quickly and spread to the liver and other organs.

Splenic rupture is a particularly dangerous complication with angiosarcoma. Because the tumor grows within the spleen’s blood-rich tissue, the organ can rupture spontaneously, causing life-threatening internal bleeding. The same study found that splenic rupture was an independent predictor of worse survival. Chemotherapy after surgery improved outcomes somewhat, but even with aggressive treatment, the disease remains overwhelmingly fatal within a year or two for most patients. Among all types of splenic cancer, angiosarcoma is the one where survival statistics offer the least hope.

When Cancer Spreads to the Spleen From Elsewhere

The spleen can also become a site of metastatic disease, meaning a cancer that started in another organ has spread there. This is uncommon because the spleen’s immune microenvironment tends to resist colonization by circulating tumor cells, but it does happen, most often with cancers of the lung, colon, breast, and ovary. When it does, the prognosis is generally poor. A PET/CT-based study found that after detection of splenic metastasis, the median overall survival was about seven months, with one-year and two-year survival rates of roughly 32 percent and 28 percent.⁸ Patients whose primary cancer was in the lung did worse still, with more than double the risk of death compared with patients whose cancer had originated elsewhere.

There is an important exception. When the spleen is the only site of metastatic spread and the metastasis appears months or years after the original cancer was treated, outcomes can be surprisingly good with surgical removal. A study of patients with isolated splenic metastases from colorectal cancer who underwent splenectomy found estimated one-year and five-year overall survival rates of 96 percent and 78 percent, respectively.⁹ Those numbers are dramatically better than the overall metastatic-disease figures, largely because an isolated splenic metastasis represents a very different situation than widespread cancer. In an odd finding from that same study, patients under 62 actually had worse overall survival after splenectomy than those 62 and older, for reasons that remain unclear.

How Splenectomy Fits Into Treatment

Removing the spleen is a common thread across many types of splenic cancer, but its impact on survival depends heavily on the specific disease. For splenic DLBCL, splenectomy at diagnosis appears to improve progression-free survival, particularly in early-stage disease.⁶ For SMZL, the picture is less clear-cut. A large analysis using the National Cancer Data Base found no clear association between splenectomy and overall survival across all lymphoma types involving the spleen. However, among DLBCL patients specifically, those who did not receive chemotherapy after a diagnostic splenectomy had significantly worse survival, suggesting that surgery alone is not enough and systemic treatment remains essential.¹⁰

For angiosarcoma, splenectomy is often performed as an emergency measure when the spleen ruptures, and even in planned surgeries, the cancer’s tendency to spread quickly limits the benefit of removing the primary tumor. The pattern that emerges is that splenectomy helps most when the cancer is localized and when it is combined with appropriate drug therapy afterward.

The Hepatitis C Connection

One of the more striking findings in splenic lymphoma research is the connection between hepatitis C virus (HCV) infection and certain types of splenic lymphoma, particularly the villous lymphocyte variant of SMZL. In a study published in the New England Journal of Medicine, nine patients with HCV-positive splenic lymphoma were treated with antiviral therapy rather than cancer-directed treatment. Seven achieved complete remission after the virus became undetectable in their blood, and the remaining two also achieved remission after adding a second antiviral drug. One patient relapsed when the virus came back. Meanwhile, none of the six HCV-negative patients in the study responded to the same antiviral therapy.¹¹

This means that for a subset of patients with splenic lymphoma, the cancer is being driven by chronic viral infection, and treating the infection can make the lymphoma regress without traditional cancer therapies. With today’s highly effective antiviral treatments for hepatitis C, this is a genuinely actionable finding. If you or someone you know is diagnosed with SMZL, hepatitis C testing is a standard part of the workup for this reason.

Splenic Rupture as a Complication

Whether caused by angiosarcoma, lymphoma, or leukemia, spontaneous rupture of a cancerous spleen is a medical emergency with its own grim survival statistics. A study of splenic rupture in patients with hematologic malignancies found that about half of patients underwent emergency surgery and half died before reaching the operating room. Among those who did have surgery, 78 percent survived the procedure and the immediate recovery period. Overall, the survival rate across all patients was 38 percent.¹² The strongest predictor of survival was whether the patient received timely surgery, not the type of malignancy, blood counts, or spleen size.

This is relevant because some splenic cancers, especially angiosarcoma, carry a high risk of rupture. The cancer weakens the organ’s tissue and makes it prone to hemorrhage, sometimes before the cancer itself has even been diagnosed. Abdominal pain, a falling blood count, and signs of internal bleeding in someone with a splenic mass should be treated as urgent.

Telling Benign From Malignant Splenic Lesions

Many splenic lesions are discovered incidentally during imaging for another reason, and the first question is always whether the finding is cancerous. Benign lesions like cysts and hemangiomas can look similar to malignancies on scans, creating real diagnostic challenges.¹³ Certain patterns on contrast-enhanced CT scans and PET/CT scans help distinguish the two. Low-density spots and areas of diffusely increased metabolic activity tend to point toward malignancy, while dense focal lesions and cystic patterns are more often benign.¹⁴ Still, imaging alone is rarely definitive, and biopsy or splenectomy may be needed to reach a diagnosis. The important point for anyone facing this situation is that a splenic lesion found on a scan is much more likely to be benign than malignant, and the imaging characteristics can offer meaningful reassurance in many cases.

Life After Splenectomy

For patients who do have their spleen removed as part of cancer treatment, the surgery trades one set of risks for another. The spleen plays an important role in filtering bacteria from the bloodstream, and losing it raises the lifetime risk of serious infections. Overwhelming post-splenectomy infection (OPSI) is a syndrome of rapid, fulminant sepsis that carries high mortality and can strike years or even decades after the surgery.¹⁵ The risk is highest in the first two years after surgery but never fully goes away.

Prevention involves three pillars: vaccinations against encapsulated bacteria (especially pneumococcus, meningococcus, and Haemophilus influenzae), sometimes a course of prophylactic antibiotics in the early post-surgery period, and patient education about seeking immediate medical care for any fever or signs of infection. People who have had their spleen removed also carry a medical alert card or bracelet so that emergency responders know about their increased vulnerability. While OPSI is rare in absolute terms, it progresses so fast when it does occur that awareness is genuinely lifesaving.

Palliative Radiation for Symptomatic Spleen Enlargement

When splenic cancer causes the organ to swell painfully but the disease is not curable, low-dose radiation to the spleen can offer meaningful relief. A systematic review of splenic irradiation found that 85 to 90 percent of treated patients experienced at least a partial response in terms of pain, early fullness after eating, or low blood counts caused by the enlarged spleen trapping blood cells.¹⁶ About 30 percent needed retreatment within six to twelve months, but the review found that lower radiation doses seemed to work about as well as higher ones, which means the treatment can be repeated with limited cumulative toxicity.

A separate study reported similar findings: splenic size shrank in about 79 percent of treatment courses, anemia improved in 75 percent, and low platelet counts improved in roughly 64 percent. Patients with chronic blood cancers like myeloproliferative disorders had a median survival of 45 months after palliative splenic radiation, while those with more aggressive lymphomas had shorter survival. Patients who responded to the radiation lived significantly longer than those who did not, with a median survival of 45 months versus 16 months.¹⁷ Splenic irradiation does not cure the underlying cancer, but for patients dealing with a painfully enlarged spleen and limited treatment options, it reliably improves quality of life.

Predicting Individual Outcomes

Because primary splenic lymphoma encompasses several different subtypes with different behaviors, researchers have developed prediction tools called nomograms that weigh multiple patient and disease characteristics together. A study using the SEER cancer registry built separate models for overall survival and disease-specific survival in primary splenic lymphoma, incorporating factors like age, cancer stage, specific lymphoma subtype, and whether chemotherapy or surgery was performed.¹⁸ These tools are designed for clinicians to generate individualized survival estimates rather than relying on population-level averages that may not reflect a given patient’s situation.

The practical lesson is that population survival statistics, including all the numbers discussed in this article, represent averages across many patients with varying ages, stages, and health statuses. A young, otherwise healthy person with early-stage SMZL and no unfavorable blood markers is in a very different position from an elderly patient with advanced angiosarcoma and a ruptured spleen. The range of outcomes within “spleen cancer” is wider than in almost any other organ-specific cancer category, which makes personalized risk assessment with a specialist more valuable than any general-population figure.